Steroid Eye Drops After Ocular Surgery: A Practical Guide to Selection, Tapering and IOP Safety

Topical corticosteroids are the backbone of postoperative inflammation control, yet they are also the class most likely to cause preventable harm in the postoperative period — through steroid-induced ocular hypertension, delayed epithelial healing, infection potentiation and rebound inflammation from abrupt withdrawal. The surgeon's task is to match steroid potency to inflammatory burden, taper predictably, and monitor intraocular pressure (IOP) with the same diligence applied to the wound. This guide distils the evidence and practical experience relevant to Indian practice.

Why Steroids After Surgery

Even an immaculate phacoemulsification triggers prostaglandin- and cytokine-mediated anterior segment inflammation: anterior chamber cells and flare, fibrin in severe cases, pain, photophobia and, if uncontrolled, posterior synechiae, secondary IOP elevation and cystoid macular oedema (CME). Steroids act upstream — inhibiting phospholipase A2 and thereby both cyclo-oxygenase and lipoxygenase pathways — giving broader anti-inflammatory coverage than NSAIDs alone. Postoperative steroid use is therefore not optional comfort care; it is structural protection for the visual outcome.

Potency and Formulation: Choosing the Molecule

The loteprednol evidence

Loteprednol etabonate is a "soft steroid" — designed to be rapidly metabolised to inactive metabolites after exerting local effect. The pivotal double-masked studies (Stewart et al., J Cataract Refract Surg 1998; and the Loteprednol Postoperative Inflammation Study Group 2, Ophthalmology 1998) established superiority over vehicle for post-cataract inflammation. Lane and Holland (JCRS 2013) showed loteprednol 0.5% provided inflammation control equivalent to prednisolone acetate 1% after routine cataract surgery, with a trend toward lower IOP change. In known steroid responders, Bartlett et al. (J Ocul Pharmacol 1993) demonstrated a significantly attenuated IOP rise with loteprednol versus prednisolone. For the estimated one-third of the population who are steroid responders — and for paediatric eyes, where response rates are higher still — this safety margin is clinically decisive.

Steroid Response and IOP: The Safety Core

A clinically significant steroid response (IOP rise ≥6 mmHg, or >21 mmHg absolute) appears in roughly 5–6% of the general population as high responders and up to a third as moderate responders; risk is amplified in glaucoma patients, first-degree relatives of POAG patients, diabetics, high myopes and children. Practical rules:

• Check IOP at every postoperative visit, not just day 1. Steroid responses typically declare at 2–6 weeks — often after the surgeon has discharged the patient.
• If IOP rises on treatment: reduce potency or frequency rather than stopping anti-inflammatory cover entirely; add an IOP-lowering agent if needed; switch to loteprednol or fluorometholone where inflammation permits.
• Document a taper schedule in the discharge summary — patients seen elsewhere mid-course should be able to reconstruct the plan.

Tapering: How and Why

Inflammation after routine phacoemulsification follows a predictable decay, and the taper should shadow it. A typical uncomplicated course:

• Week 1: QID
• Week 2: TID
• Week 3: BD
• Week 4: OD, then stop

Adjust for inflammatory burden: dense cataracts, prolonged surgery, posterior capsule rupture, uveitic or diabetic eyes all warrant slower tapers. Never stop a steroid abruptly after more than 2–3 weeks of use in an actively inflamed eye — rebound inflammation is common and undermines an otherwise good result. Equally, avoid the opposite sin of indefinite low-dose steroids "for comfort", which invites IOP problems, infection and ocular surface disease.

Difluprednate and the Potent End of the Spectrum

For inflammation that routine-potency steroids cannot hold — fibrinous postoperative reactions, recurrent uveitis flares, scleritis-adjacent inflammation — difluprednate 0.05% emulsion offers potency exceeding prednisolone acetate with twice-daily dosing. The pivotal JCRS data (Korenfeld et al., 2009) established its efficacy for postoperative inflammation and pain. The trade is a steeper IOP-response curve: difluprednate demands the most disciplined pressure monitoring of any topical steroid and has no place as a routine post-cataract default. Reserve it for defined, reviewed indications, and never issue it as a repeatable prescription.

Steroid Complications Beyond IOP

Intraocular pressure dominates the safety conversation, but the postoperative surgeon should keep the full list in view:

• Infection potentiation: steroids accelerate herpes simplex epithelial disease, fungal keratitis and bacterial infection; any worsening "inflammation" on full-dose steroid is an infection question until proved otherwise.
• Delayed epithelial and stromal healing: relevant to the post-PRK surface, corneal grafts and any coexisting epithelial defect.
• Posterior subcapsular cataract: the long-game complication of chronic courses in graft and uveitis patients.
• Rebound inflammation from abrupt withdrawal, already discussed, and tachyphylaxis in eyes kept on indefinitely prolonged low doses.
• Ptosis and mydriasis with prolonged use — cosmetic, but noticed by patients.

The discipline that prevents most steroid misadventures is unglamorous: the fewest drops of the least potent molecule for the shortest effective time, with IOP measured at every visit and a stop date written at initiation.

Interactions with the Rest of the Post-op Regimen

Steroids are rarely the only bottle in the regimen. Sequence matters: instil antibiotic first, steroid second, lubricant last, spacing each by at least five minutes. Where inflammation and infection prophylaxis can be combined in a single bottle, adherence improves measurably — preservative-free combinations such as Moxilux-LP (moxifloxacin with loteprednol) or Moxilux-D (moxifloxacin with dexamethasone) are rational choices for the first 2–3 postoperative weeks, after which a standalone taper can continue if required. An NSAID such as nepafenac added for CME prophylaxis in at-risk eyes runs in parallel, not in place of, the steroid.

What the Taper Is Actually Treating: Reading the Anterior Chamber

Steroid adjustment should be driven by graded inflammation, not the calendar alone. At each review, grade anterior chamber cells against a standard scale (0, trace, 1+, 2+, 3+, 4+), note flare, and inspect for keratic precipitates, fibrin and synechiae. A 2+ cellular reaction at week one justifies intensifying frequency before the scheduled taper; a quiet chamber at week two in a routine case justifies proceeding on schedule, not extending "to be safe". Equally, persistent inflammation out of proportion to the surgery should prompt a diagnostic re-think — retained lens fragment, low-grade infection including Cutibacterium acnes, iris chafe from a malpositioned IOL, or early endophthalmitis — rather than reflex steroid escalation. The taper is a default trajectory; the slit lamp is the steering wheel.

Why Steroids Raise IOP: A Mechanism Worth Remembering

Corticosteroids increase outflow resistance at the trabecular meshwork by altering glycosaminoglycan metabolism and inducing cytoskeletal changes in trabecular cells — the meshwork becomes, in effect, less permeable to aqueous. The response is dose-, potency- and duration-dependent, genetically influenced, and largely reversible on withdrawal if caught early. The rise typically appears after two to six weeks of therapy, which is why day-one pressures are falsely reassuring. Two corollaries follow. First, route matters: topical drops, periocular injections and intravitreal implants carry escalating risk, but even nasal and dermatological steroids contribute in susceptible patients. Second, the risk never fully disappears on continued therapy — late responses after months of quiet IOP are documented, so vigilance must persist for as long as the prescription does.

Building the Monitoring Schedule Into the Discharge Plan

A monitoring plan that lives only in the surgeon's head fails. For a routine case, a defensible minimum is:

• Day 1: wound, IOP (transient spikes from retained viscoelastic are common and are not steroid response), inflammation grade.
• Week 1–2: inflammation grade, IOP, adherence check; adjust the regimen.
• Week 4–6: end of taper; final IOP before discharge, refraction as appropriate.

Any patient on steroids beyond six weeks — grafts, uveitic eyes, paediatric cases — needs IOP checked at least monthly while on treatment. Communicate this explicitly to patients travelling back to district towns, and name a local ophthalmologist where possible; steroid response detected at month three by a stranger is a failure of planning, not of pharmacology.

Adherence: The Unmeasured Variable

Postoperative regimens fail less often from wrong molecule selection than from wrong administration. Elderly patients with arthritic hands, rural patients without caregivers, and anyone juggling three bottles four times a day will default to the easiest ritual — usually the steroid alone, because it makes the eye feel best. Mitigations with proven value: fixed-combination drops to cut bottle count; written and pictorial schedules in the patient's language; caregiver training before discharge; and explicit instruction to shake suspensions (loteprednol and prednisolone acetate settle — an unshaken bottle delivers a fraction of the dose).

Special Situations

• Paediatric cataract: higher inflammatory drive, higher steroid-response risk; loteprednol-based regimens with intensive early dosing and close IOP surveillance are preferred.
• Uveitic cataract: begin preoperative steroids, extend postoperative courses to months, and taper against slit-lamp activity rather than the calendar.
• Glaucoma patients: choose loteprednol or fluorometholone where possible; coordinate with the glaucoma service before potent agents.
• Corneal grafts: prolonged low-dose steroids are deliberate and necessary, with lifelong vigilance for rejection and IOP.

Frequently Asked Questions

How long should steroid eye drops be used after cataract surgery?

For uncomplicated phacoemulsification, a tapering course over 3–4 weeks (QID → OD) is standard. Complex surgery, uveitis or diabetic eyes may need 6–8 weeks with a slower taper guided by anterior chamber activity.

Which is better after surgery: loteprednol or prednisolone?

Randomised data (Lane & Holland, JCRS 2013) show equivalent inflammation control, with loteprednol carrying a materially lower IOP-elevation risk. Loteprednol is preferred in steroid responders, children and glaucoma suspects; prednisolone for severe inflammation.

How is a steroid responder managed postoperatively?

Confirm the rise is steroid-related (temporal pattern, no other cause), switch to a lower-potency steroid (loteprednol/fluorometholone) or reduce frequency, add topical IOP-lowering therapy if needed, and monitor weekly until stable. Do not simply stop all anti-inflammatory therapy.

Can steroid eye drops delay corneal healing?

Yes — steroids inhibit fibroblast activity and collagen synthesis and potentiate infection. In epithelial defects, persistent erosion or active microbial keratitis, minimise steroid exposure and reassess the diagnosis before continuing.

Should steroids be stopped abruptly?

No. After courses longer than 2–3 weeks, taper the frequency before stopping. Abrupt withdrawal in an eye with residual inflammation produces rebound anterior chamber activity and occasionally IOP spikes.

---

This article is for educational purposes for healthcare professionals and does not replace clinical judgement. Steroid selection, tapering and IOP monitoring must be individualised by the treating surgeon.

Oculentis Medical offers preservative-conscious steroid and combination formulations for postoperative care. To evaluate Moxilux-LP in your postoperative protocol, request a sample or contact our team.